Allakos Inc (ALLK)

Allakos (ALLK) Stock Price & Analysis


ALLK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.54 - $8.73
Previous Close$7.37
Average Volume (3M)1.09M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$325.32M
Total Debt (Recent Filing)$49.84M
Price to Earnings (P/E)-1.1
Next EarningsFeb 28, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-6.76
Shares Outstanding85,203,597
Standard Deviation0.31
10 Day Avg. Volume892,300
30 Day Avg. Volume1,090,208
Price to Book (P/B)1.93
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside67.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Allakos’s price range in the past 12 months?
Allakos lowest stock price was $2.54 and its highest was $8.73 in the past 12 months.
    What is Allakos’s market cap?
    Currently, no data Available
    When is Allakos’s upcoming earnings report date?
    Allakos’s upcoming earnings report date is Feb 28, 2023 which is in 29 days.
      How were Allakos’s earnings last quarter?
      Allakos released its earnings results on Nov 07, 2022. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.755 by $0.225.
        Is Allakos overvalued?
        According to Wall Street analysts Allakos’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Allakos pay dividends?
          Allakos does not currently pay dividends.
          What is Allakos’s EPS estimate?
          Allakos’s EPS estimate is -$0.5.
            How many shares outstanding does Allakos have?
            Allakos has 85,203,600 shares outstanding.
              What happened to Allakos’s price movement after its last earnings report?
              Allakos reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.755. Following the earnings report the stock price went up 15.523%.
                Which hedge fund is a major shareholder of Allakos?
                Among the largest hedge funds holding Allakos’s share is Fairmount Funds Management Llc. It holds Allakos’s shares valued at 901K.


                  Allakos Stock Smart Score

                  The Allakos stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Allakos Inc

                  Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Anavex Life Sciences
                  iTeos Therapeutics
                  Mirum Pharmaceuticals
                  Editas Medicine
                  POINT Biopharma Global

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis